Search Details

Word: accessibility (lookup in dictionary) (lookup stats)
Dates: during 2000-2009
Sort By: most recent first (reverse)


Usage:

This month, the world’s second largest pharmaceutical company, GlaxoSmithKline, startled the drug industry and the public-health world by announcing a groundbreaking program intended to extend access to medicines for millions of people living in developing countries. GSK’s proposal is not a perfect solution: Millions of patients in middle-income countries, such as India and Brazil, will be left out of the deal. HIV research is also excluded from parts of the program, and even at reduced prices GSK products may remain out of reach for most patients in Least Developed Countries. Nevertheless...

Author: By Karolina Maciag, Shamsher S. Samra, and Sarah E. Sorscher | Title: Harvard as Big Pharma | 3/1/2009 | See Source »

Every time a 13-year-old in rural Peru or Tuvalu touches a keyboard, she bypasses the Industrial Revolution and rockets into the Information Age. She can network, learn calculus, study crop-growing techniques, or e-mail a hospital for advice on illness treatment. She can access a wealth of knowledge beyond the horizon fortune has aligned for her. But how much does it really help? Lately, efforts to bring computers to youth in developing areas have been assaulted as ineffective, or even worse—impulsively imperialistic. Last month, One Laptop per Child—an NGO aiming...

Author: By Raúl A. Carrillo | Title: One Laptop, Much Controversy | 2/27/2009 | See Source »

Though malaria is both preventable and curable, many of those in the developing world struggle to get affordable treatment, particularly in sub-Saharan Africa, where the mosquito-borne disease is most prevalent. Blame for that lack of access has been laid largely at the feet of Big Pharma, long vilified for pricing medicine beyond the poor's reach and ignoring diseases that are endemic in poverty-stricken areas...

Author: /time Magazine | Title: A Better Deal on Malaria | 2/26/2009 | See Source »

...part, Novartis now spends more than $1 billion a year on ensuring better access to medicines. The firm has built two research labs dedicated to preventing and curing neglected diseases such as dengue fever and tuberculosis and has pledged to eradicate leprosy. (Read "A Vaccine That Could Help Wipe Out Malaria...

Author: /time Magazine | Title: A Better Deal on Malaria | 2/26/2009 | See Source »

...which has already provided $39 billion in emergency loans to shore up Eastern European economies, is discussing a regional bailout package. But the Fund is also struggling; with access to $200 billion in funds, its ability to step in is limited. "So far we've seen disappointing tendencies on the part of Western European governments moving in a more protectionist direction, which is worrying," says Christensen. "But the pressure is increasing on policy makers to find some kind of solution...

Author: /time Magazine | Title: The Economic Crisis Hits Eastern Europe | 2/25/2009 | See Source »

Previous | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | Next